(NASDAQ: SLS) Sellas Life Sciences Group's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 6.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 54.34%.
Sellas Life Sciences Group's earnings in 2025 is -$26,259,000.On average, 1 Wall Street analyst forecast SLS's earnings for 2025 to be -$29,483,291, with the lowest SLS earnings forecast at -$29,483,291, and the highest SLS earnings forecast at -$29,483,291.
In 2026, SLS is forecast to generate -$40,013,038 in earnings, with the lowest earnings forecast at -$40,013,038 and the highest earnings forecast at -$40,013,038.